Neuberger Berman Group
TVTX icon

Neuberger Berman Group’s Travere Therapeutics TVTX Stock Holding History

Neuberger Berman Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.67M Sell
190,762
-27,265
-13% -$815K ﹤0.01% 957
2025
Q4 		$8.33M Buy
218,027
+6,360
+3% +$207K 0.01% 849
2025
Q3 		$5.06M Buy
+211,667
New +$3.98M ﹤0.01% 964
2018
Q3 		– Sell
-17,000
Closed -$463K – 1704
2018
Q2 		$463K Sell
17,000
-10,000
-37% -$266K ﹤0.01% 1409
2018
Q1 		$604K Buy
+27,000
New +$643K ﹤0.01% 1318

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group's TVTX Position: Q1 2026 in Review

Neuberger Berman Group reduced its Travere Therapeutics (TVTX) stake by 13% in Q1 2026, selling an estimated $815K and leaving 190,762 shares worth $5.67M. The position accounts for ﹤0.01% of the portfolio, ranked #957.

Neuberger Berman Group first reported a position in TVTX in Q1 2018 and has held it in 5 quarters since. The position peaked at $8.33M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Neuberger Berman Group held 190,762 shares of Travere Therapeutics worth $5.67M as of Q1 2026.
  • Neuberger Berman Group sold 27,265 Travere Therapeutics shares in Q1 2026, an estimated $815K.
  • Travere Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #957 holding.
  • Neuberger Berman Group first reported a position in Travere Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • Neuberger Berman Group's Travere Therapeutics position peaked at $8.33M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.